Beijing Scitop Bio-tech Co (300858) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached ¥80.66 million, up 4.74% year-over-year; net profit attributable to shareholders was ¥27.68 million, down 12.62% year-over-year.

• Net profit for the first nine months was ¥71.19 million, a slight decrease of 1.13% compared to the same period last year.

• Adjusted net profit (excluding non-recurring items) for Q3 was ¥23.46 million, down 18.62% year-over-year.

Financial highlights

• Operating cash flow for the first nine months was ¥107.66 million, up from ¥81.28 million year-over-year.

• Basic and diluted EPS for the first nine months were both ¥0.27, unchanged year-over-year.

• Total assets at quarter-end were ¥1.85 billion, up 2.24% from the previous year-end.

• Owner's equity attributable to shareholders was ¥1.76 billion, up 1.83% from year-end.

• Non-recurring gains for the first nine months totaled ¥10.09 million, mainly from government subsidies and fair value changes.

Outlook and guidance

• Management adjusted the restricted stock incentive plan grant price from ¥13.00 to ¥12.85 per share in Q3 2024.